|MDACC Study No:||ECOGE3F05 (clinicaltrials.gov NCT No: NCT00978458)|
|Title:||Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas|
|Principal Investigator:||John DeGroot|
|Treatment Agent:||Radiation; Temozolomide|
|Study Description:||The goal of this clinical research study is to learn if adding temozolomide to |
radiation therapy can help to control low-grade glioma better than treatment
with standard radiation therapy alone. The safety of this treatment
combination will also be studied.
The radiation therapy in this study is designed to stop the reproduction and
repair of cancer cells by damaging the DNA (the genetic material of cells).
The damaged DNA may cause tumor cell death. Radiation therapy is the commonly
used standard of care for low-grade glioma.
Temozolomide is also designed to damage the DNA of cancer cells. The damaged
DNA may cause tumor cell death.